All In MedTech

FDA Clearance Tracker · P190030-S004

ActaStim-S

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 13, 2026

Approved

Time to decision

499 days

Received Dec 30, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class II

The decision

FDA number
P190030-S004
Device name
ActaStim-S
Applicant location
Manassas, VA
Received
Dec 30, 2024
Decided
May 13, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190030

Device type

Device class
Class II
Regulation
21 CFR 890.5870

Every decision under product code LOF

FDA's approval statement

As written in FDA's record.

Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.

Source documents

Other decisions for Theragen, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.